Merck (MRK) announced on Thursday that the European Commission approved its anti-PD-1 therapy Keytruda in combination with chemotherapy (paclitaxel) as a late-line option for certain adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results